Last quarter (Q4 2023), PharmAla Biotech Holdings, Inc.'s total revenue was C$583.04K, an increase of Infinity% from the same quarter last year. In Q4, PharmAla Biotech Holdings, Inc.'s net income was C$36.48K. See PharmAla Biotech Holdings, Inc.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Aug 23	Aug 22	Aug 21
Total Revenue	C$ 1.12M	C$ 532.00K	C$ 78.07K	C$ 0.00
Cost of Revenue	C$ 370.86K	C$ 77.90K	C$ 2.29K	C$ 0.00
Gross Profit	C$ 744.18K	C$ 454.10K	C$ 75.78K	C$ 0.00
Operating Expense	C$ 1.20M	C$ 1.23M	C$ 1.06M	C$ 2.51M
Operating Income	C$ -454.83K	C$ -779.81K	C$ -985.58K	C$ -2.51M
Net Non Operating Interest Income Expense	-	-	-	-
Other Income Expense	-	-	-	-
Pretax Income	C$ -454.83K	C$ -779.81K	C$ -985.58K	C$ -2.51M
Tax Provision	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-
Net Income Common Stockholders	C$ -454.83K	C$ -779.81K	C$ -985.58K	C$ -2.51M
Basic EPS	-	C$ -0.01	C$ -0.01	C$ -0.03
Diluted EPS	-	C$ -0.01	C$ -0.01	C$ -0.03
Basic Average Shares	C$ 341.59M	C$ 84.53M	C$ 79.76M	C$ 83.00M
Diluted Average Shares	C$ 341.59M	C$ 84.53M	C$ 79.76M	C$ 83.00M
Dividend Per Share	-	-	-	-
Total Operating Income As Reported	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-
Rent Expense Supplemental	-	-	-	-
Total Expenses	C$ 1.57M	C$ 1.31M	C$ 1.06M	C$ 2.51M
Net Income From Continuing And Discontinued Operation	C$ -454.83K	C$ -779.81K	C$ -985.58K	C$ -2.51M
Normalized Income	C$ -325.00K	C$ -573.16K	C$ -724.40K	C$ -2.51M
Interest Expense	-	-	-	-
EBIT	C$ -454.83K	C$ -779.81K	C$ -985.58K	C$ -2.51M
EBITDA	C$ -399.46K	C$ -727.05K	C$ -973.45K	C$ -2.51M

Currency in CAD

PharmAla Biotech Holdings, Inc. Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing